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The C-type lectin-like receptor CLEC-2 signals via phos-
phorylation of a single cytoplasmic YXXL sequence known as a
hem-immunoreceptor tyrosine-based activation motif (hemI-
TAM). In this study, we show that phosphorylation of CLEC-2
by the snake toxin rhodocytin is abolished in the absence of
the tyrosine kinase Syk but is not altered in the absence of the
major platelet Src family kinases, Fyn, Lyn, and Src, or the ty-
rosine phosphatase CD148, which regulates the basal activity
of Src family kinases. Further, phosphorylation of CLEC-2 by
rhodocytin is not altered in the presence of the Src family kinase
inhibitor PP2, even though PLC2 phosphorylation and platelet
activation are abolished. A similar dependence of phosphoryla-
tion of CLEC-2 on Syk is also seen in response to stimulation by
an IgG mAb to CLEC-2, although interestingly CLEC-2 phos-
phorylation is also reduced in the absence of Lyn. These results
provide the first definitive evidence that Syk mediates phos-
phorylation of the CLEC-2 hemITAM receptor with Src family
kinases playing a critical role further downstream through the
regulation of Syk and other effector proteins, providing a new
paradigm in signaling by YXXL-containing receptors.
The C-type lectin-like receptor CLEC-2 is a type II trans-
membrane protein that is highly expressed on the surface of
platelets and megakaryocytes (1, 2) and at a lower level on
several other hematopoietic lineages, including monocytes
and dendritic cells (3–5). The first ligand to be identified for
CLEC-2 was the powerful snake venom toxin, rhodocytin,
purified from the Malayan pit viper, Calloselasma rhodostoma
(2). F(ab)2 antibody fragments of CLEC-2 antibodies were
subsequently shown to mediate activation of human platelets
(2, 6). The transmembrane protein podoplanin was identified
as an endogenous ligand, inducing powerful activation of
platelets and CLEC-2-expressing cell lines (2, 6–8). Podopla-
nin is expressed on the surface of a wide variety of cells such
as kidney podocytes, lung type I alveolar cells, and lymphatic
endothelial cells but is absent from vascular endothelial cells
and platelets. The activation of CLEC-2 by podoplanin is es-
sential for the separation of the lymphatic and blood vascula-
tures (9–12). In addition, the expression of podoplanin on the
surface of certain tumors is implicated in the process of tu-
mor metastasis through activation of CLEC-2 (8, 13). CLEC-2
has recently been reported to play a role in supporting platelet
activation at arteriolar rates of flow on collagen in some (6,
11) but not all studies (14).
CLEC-2 is expressed on resting platelets as a noncovalent
homodimer (15, 16) and signals through a single YXXL se-
quence in its cytoplasmic tail known as a hem-immunorecep-
tor tyrosine-based activation motif (hemITAM)
8 (2, 15–17).
The minimal signaling unit for activation of Syk by CLEC-2
has been proposed to be the cross-linking of two CLEC-2
dimers (15, 16), activating a similar signaling cascade to that
of the platelet collagen receptor GPVI-FcR-chain complex,
with critical roles for LAT (linker for activation of T cells),
SLP-76 (Src homology 2 domain-containing leukocyte protein
of 76 kDa), phosphoinositide 3-kinases, and phospholipase C
(PLC) 2 (2, 17). CLEC-2 signaling occurs in lipid rafts and is
dependent on actin polymerization, release of the secondary
mediators ADP and thromboxane A2, and activation of the
small G protein Rac (18).
Phosphorylation of the GPVI-FcR-chain ITAM is medi-
ated by Src family kinases leading to subsequent binding and
activation of Syk. Thus, ITAM phosphorylation is preserved
in the absence of Syk or the Syk inhibitor R406 (19, 20). The
Src family kinases Lyn and Fyn mediate phosphorylation of
the GPVI-FcR-chain ITAM (21–23). Fyn and Lyn bind to a
proline-rich region in the cytosolic tail of GPVI via their Src
homology 3 domains, allowing for rapid initiation of platelet
activation (21, 24). In addition, they also support activation by
a second pathway of activation that is independent of the
GPVI proline-rich motif (25). Recently, it has been proposed
that GPVI-associated Lyn is in an active conformation, sug-
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Supplemental Material can be found at:gesting that Lyn initiates GPVI-induced platelet activation,
with Fyn supporting sustained GPVI signaling (23).
Src family kinases also play a role in CLEC-2-mediated
signaling, because structurally distinct broad range Src
family kinase inhibitors such as PP2 and PD 173956 inhibit
human platelet activation (2, 17). However, it has recently
been reported that phosphorylation of CLEC-2 in human
platelets stimulated by rhodocytin is blocked by selective
inhibitors of Src family or Syk tyrosine kinases, implicating
these kinases in hemITAM phosphorylation (20). One po-
tential explanation for these observations is that Syk medi-
ates CLEC-2 phosphorylation and that Src family kinases
regulate Syk. Thus, the proximal events in signaling by
hemITAM receptors appear to be distinct from those used
by ITAM receptors.
In the present study, we have investigated the molecular
events underlying CLEC-2 phosphorylation in mouse platelets
using mutant mice deficient in the major platelet Src family
kinases (Fyn, Lyn, and Src), the tyrosine kinase Syk, and the
global regulator of Src family kinases in platelets, CD148. The
results provide the first demonstration that Syk and not Src
family kinases mediate hemITAM phosphorylation and iden-
tify Src family kinases regulating platelet activation down-
stream of Syk.
EXPERIMENTAL PROCEDURES
Reagents—Rhodocytin was purified from C. rhodostoma
venom as described previously (2). Rat anti-mouse CLEC-2
IgG mAb and rabbit anti-Syk (BR15) polyclonal antibody were
from previously described sources (4, 26). CLEC-2 IgM anti-
body was a gift from Dr. Caetano Reis e Sousa. Hamster anti-
mouse CD148 antibody (8A-1) was generated as described
(27). Mouse anti-phosphotyrosine antibody 4G10 was pur-
chased from Upstate Biotechnology Inc. pY1217 PLC2
antibody was from Cell Signaling Technology. HRP-conju-
gated secondary anti-rabbit IgG and -bind protein
G-Sepharose were from GE Healthcare. Anti-rat Fc anti-
body was from Abcam. All other reagents were purchased
from Sigma-Aldrich.
Animals—fyn
/, lyn
/, and src
/ breeding pairs were
from Jackson Laboratories (Bar Harbor, ME). fyn
/ lyn
/
double knock-out mice were raised from mixed breeding of
fyn
/ and lyn
/ mice. CD148
/ mice were generated as
described previously (28). Experimental controls were wild-
type littermates. No differences were observed in platelet
function between the different wild-type controls. The mice
were genotyped by PCR amplification of mouse tail genomic
DNA. Lack of protein expression was confirmed by Western
blotting platelet lysates. The mice were housed under specific
pathogen-free conditions in accordance with institutional
guidelines approved by United Kingdom Home Office and
were used between 8 and 12 weeks of age.
Generation of Chimeric Mice—Radiation chimeras were
generated as described previously (19). Briefly, 8-week-old
C57BL/6 mice received two doses of irradiation each of 500
Gy 3 h apart. The mice were then reconstituted with an intra-
venous injection of 1–2  10
6 fetal liver cells obtained from
embryonic days 14–16 lyn
/ src
/, lyn
/ src
/, fyn
/
src
/, fyn
/ src
/, syk
/, syk
/, and clec-2
/ or clec-
2
/ mouse livers. The genotype of the reconstituting fetal
liver cells was confirmed in each case by PCR. Lack of protein
expression was confirmed by Western blotting platelet ly-
sates. Reconstituted mice were used for experiments at 8
weeks after irradiation.
Preparation of Mouse Platelets—Whole blood was drawn
from the inferior vena cava into acid citrate dextrose (1⁄9 vol-
ume) from CO2-asphyxiated mice following isofluorane anes-
thesia. Washed mouse platelets were obtained as described
previously (29). Briefly, platelets were obtained by centrifuga-
tion using prostaglandin I2 to prevent activation during the
isolation procedure. Washed platelets were then resuspended
in modified HEPES Tyrode buffer (134 mM NaCl, 2.9 mM KCl,
12 mM NaHCO3, 0.34 mM NaH2PO4,1m M MgCl2, 5.5 mM
glucose, 1 mM MgCl2,2 0m M HEPES, and 5 mM glucose, pH
7.3) at a density of 2  10
8 platelets/ml. Aggregation was
monitored by light transmission using a Born lumi-aggre-
gometer (Chronolog, Havertown, PA).
Immunoprecipitation Studies—Washed resting or stimulated
platelets (300 la t210
8platelets/ml) were lysed with an equal
volume of 2Nonidet P-40 lysis buffer (20 mMTris-HCl, pH
7.6, 300 mMNaCl, 2 mMEGTA, 2 mMEDTA, 2% Nonidet P-40,
2m MPMSF, 5 mMNa3VO4,1 0g/ml leupeptin, 10 g/ml apro-
tinin, 1 g/ml pepstatin). Cell debris was removed by centrifuga-
tion at 15,000 gfor 10 min. An aliquot of whole cell lysate was
dissolved in reducing Laemmli sample buffer. Syk immunopre-
cipitation was carried out as standard protocol (30, 31). Platelet
lysate was precleared, 2 l of anti-Syk antibody and a 15-l bed
volume of protein A-Sepharose were added, and each sample
was rotated at 4 °C for 2 h. The pellet was washed four
times sequentially in lysis buffer before the addition of 20
l of reducing Laemmli sample buffer. Modifications from
standard immunoprecipitation protocols were made for
mouse CLEC-2 immunoprecipitations. The amount of
CLEC-2 mAb in each sample was normalized to 3 g. 20 l
of bed volume of -bind protein G-Sepharose was added to
each sample and allowed to capture the antibody for 1 h
with rotation at 4 °C. Following four washes with 1 lysis
buffer, 20 l of nonreducing Laemmli sample buffer was
added. 75% of the sample proteins was separated on a SDS-
polyacrylamide gel and transferred onto a PVDF mem-
brane. After blocking in 2% BSA, the membranes were in-
cubated with 4G10 antibody overnight, washed, and then
incubated with HRP-conjugated secondary antibody. Im-
munoprecipitated proteins were visualized by chemolumi-
nescence (ECL; Pierce). For CLEC-2 immunoprecipita-
tions, the remaining 25% was treated in the same way but
incubated with CLEC-2 mAb overnight.
Platelet Surface Protein Cross-linking—After platelet stimu-
lation, 1.5 mM Sulfo-EGS was added and allowed to incubate
at room temperature for 30 min. The reaction was quenched
with the addition of Tris-HCl (pH 7.5; 25 mM) and allowed to
incubate for a further 20 min at room temperature. The sam-
ples were lysed with the addition of an equal volume of 2
ice-cold Nonidet P-40 lysis buffer.
Cell Lines—CHO cells were transfected with pcDNA3 con-
taining full-length mouse podoplanin using a calcium phos-
SrcFamilyKinasesandSykinCLEC-2Signaling
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 phate transfection method. Stable transfectants were obtained
using medium containing 1 mg/ml geneticin (G418), and
clonal cell populations were obtained following serial dilu-
tions into 96-well plates. Primary human lymphatic endothe-
lial cells were obtained from Promocell GmbH (Heidelberg,
Germany) and cultured in endothelial cell growth medium
according to the manufacturer instructions. Surface expres-
sion of podoplanin was assessed by flow cytometry.
Statistical Analysis—Statistical significance was evaluated
using a two-tailed Student’s t test. A p value 0.05 was con-
sidered statistically significant.
RESULTS
Differential Role of Src Family Kinases in Platelet Activation by
a CLEC-2 Monoclonal Antibody and by Rhodocytin—A rat anti-
mouse IgG CLEC-2 monoclonal antibody (CLEC-2 mAb) in-
FIGURE 1. Dose response curves in response to CLEC-2 mAb and rhodocytin. A, CLEC-2-deficient and litter-matched wild-type washed platelets
(2  10
8 platelets/ml) were stimulated with 10 g/ml CLEC-2 mAb. B, murine washed platelets (2  10
8 platelets/ml) were stimulated with increas-
ing concentrations of CLEC-2 mAb or rhodocytin. Platelet aggregation was measured as a change in light transmission, using a lumi-aggregometer.
Representative aggregation traces are shown. The addition of the agonist is indicated by an arrowhead. The data represent the means and standard
error of at least eight independent experiments at 3 min of stimulation. C, CLEC-2 was immunoprecipitated (IP), and immunoprecipitates were im-
munoblotted with an anti-phosphotyrosine antibody and anti-CLEC-2 mAb as described under “Experimental Procedures.” The percentage of tyro-
sine phosphorylation was measured at 3 min of stimulation and is represented as the means and standard error of four independent experiments.
WB, Western blotting.
SrcFamilyKinasesandSykinCLEC-2Signaling
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 duces concentration-dependent CLEC-2 phosphorylation and
platelet aggregation, which is abolished in CLEC-2-deficient
mouse platelets (Fig. 1). The time to onset of aggregation de-
creases with increasing concentrations of antibody (Fig. 1B).
Rhodocytin also stimulated concentration-dependent phos-
phorylation with the delay in onset also decreasing with increas-
ing concentrations (Fig. 1, Band C). Concentrations of CLEC-2
mAb (10 g/ml) and rhodocytin (30 nM) that were just sufficient
to induce maximal CLEC-2 phosphorylation and aggregation
were chosen for further experiments, unless stated.
We have previously reported that CLEC-2-mediated activa-
tion of human platelets is abolished in the presence of Src
family kinase inhibitors (2, 17). Consistent with this, we show
that the Src family kinase inhibitor PP2 also blocks aggrega-
tion of mouse platelets stimulated by CLEC-2 mAb and by
rhodocytin (Fig. 2A), confirming a critical role for Src family
kinases in CLEC-2-induced platelet activation. Tyrosine phos-
phorylation of both CLEC-2 and the downstream kinase Syk
is completely blocked by PP2 in response to CLEC-2 mAb.
Strikingly, however, phosphorylation of CLEC-2 by rhodocy-
tin is not altered in the presence of PP2 (Fig. 2B). The inhibi-
tion of aggregation to the snake toxin by PP2 (Fig. 2A)i se x -
plained by the partial reduction in Syk phosphorylation and
inhibition of tyrosine phosphorylation of residue Tyr-1217 of
the downstream protein PLC2 (Fig. 2B), a residue shown to
be correlated with its activity (32). These results demonstrate
that Src family kinases do not mediate phosphorylation of
CLEC-2 in mouse platelets stimulated by rhodocytin but that
they play a role in the hemITAM phosphorylation induced by
a CLEC-2 mAb.
Distinct Roles for Fyn, Lyn, and Src in Platelet Activation by
CLEC-2—The major Src family kinases known to be ex-
pressed in mouse platelets are Fyn, Lyn, and Src, although
there is evidence for the presence of other isoforms (33, 34).
To dissect the role of individual Src family kinases in CLEC-2-
mediated signaling, we used mice deficient in the three major
platelet Src family kinases, Fyn, Lyn, or Src, after first estab-
lishing that the absence of one Src family kinase did not alter
expression of the others (supplemental Fig. S1). CLEC-2 and
IIb3 surface expression in platelets deficient in each of the
Src family kinases was similar to that of their litter-matched
controls (not shown).
Aggregation of platelets deficient in Src or Fyn induced by
CLEC-2 mAb (3 and 10 g/ml) or by rhodocytin (10 and 30
nM) were similar to those of litter-matched controls (Fig. 3,
A–C and not shown). In contrast, there was a marked delay in
the onset of aggregation to 10 g/ml CLEC-2 mAb in Lyn-
deficient platelets, with 50% aggregation being reached at
250  18 s compared with 140  6 s for control platelets (Fig.
3, A and C). There was, however, no significant change in the
time of onset or magnitude of aggregation induced by rhodo-
cytin (10 and 30 nM) in Lyn-deficient platelets (Fig. 3, B and C,
and not shown).
Phosphorylation of CLEC-2 and Syk in response to the
CLEC-2 mAb was abolished at 180 s in the absence of Lyn in
contrast to the robust response observed in control platelets.
This is consistent with the delay in platelet activation ob-
served in Lyn-deficient platelets. Phosphorylation of CLEC-2
can, however, be seen following full aggregation of Lyn-defi-
cient platelets (not shown). In contrast, a small reduction
in CLEC-2 and Syk tyrosine phosphorylation was observed in
response to the CLEC-2 mAb in Fyn-deficient platelets in
some but not all experiments, although this did not reach sta-
tistical significance (Fig. 3D). There was no change in phos-
phorylation of CLEC-2 following CLEC-2 mAb stimulation in
the absence of Src (not shown). Consistent with the results
obtained with PP2 (Fig. 2B), phosphorylation of CLEC-2 in-
duced by rhodocytin was not altered in the absence of Src,
FIGURE 2. Effect of Src family kinase inhibition on murine platelet in
response to CLEC-2 mAb and rhodocytin. A, murine washed platelets
(2  10
8 platelets/ml) were incubated for 10 min with or without 20 M PP2
and then stimulated with 10 g/ml CLEC-2 mAb or 30 nM rhodocytin. Plate-
let aggregation was measured as a change in light transmission using a
lumi-aggregometer. The addition of the agonist is indicated by an arrow-
head. Representative aggregation traces from three to six independent ex-
periments are shown. B, CLEC-2 and Syk were immunoprecipitated (IP), and
immunoprecipitates were immunoblotted with an anti-phosphotyrosine
antibody. CLEC-2 immunoprecipitates were also immunoblotted with anti-
CLEC-2 mAb as described under “Experimental Procedures.” Whole cell ly-
sates (WCL) were probed with pY1217 PLC2 antibody and reprobed with
PLC2 antibodies. The percentage of tyrosine phosphorylation was mea-
sured at 3 min of stimulation and is represented as the means and standard
error of three to six independent experiments. *, p  0.05; **, p  0.005 (sig-
nificant difference according to two-tailed Student’s t test). WB, Western
blotting.
SrcFamilyKinasesandSykinCLEC-2Signaling
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 Fyn, or Lyn (Fig. 3D and not shown). These data demonstrate
that Lyn is the major kinase involved in CLEC-2 platelet acti-
vation following CLEC-2 mAb ligation.
To investigate whether platelet activation is further de-
layed in the absence of more than one Src family kinases,
we generated mice doubly deficient in Fyn/Lyn, Lyn/Src,
and Fyn/Src. Mice doubly deficient in Fyn/Lyn were gener-
ated by breeding of heterozygotes, whereas the other two
sets of double knock-outs were generated as radiation chi-
meras as described under “Experimental Procedures.” As
FIGURE 3. Lyn plays a critical role in CLEC-2-mediated signaling by antibody ligation but is not involved in response to rhodocytin. Fyn-, Lyn-, or
Src-deficient washed platelets and their litter-matched wild-type platelets (2  10
8 platelets/ml) were stimulated with 10 g/ml CLEC-2 mAb (A)o r3 0n M
rhodocytin (B). Platelet aggregation was measured as a change in light transmission, using a lumi-aggregometer. Representative aggregation traces are
shown. The addition of the agonist is indicated by an arrowhead. C, data represent the means of the time to get 50% of aggregation and standard error of
three to six independent experiments. **, p  0.005 (significant difference versus wild type, according to two-tailed Student’s t test). D, Fyn- or Lyn-deficient
washed platelets and their litter-matched wild-type platelets (2  10
8 platelets/ml) were stimulated with 10 g/ml CLEC-2 mAb or 30 nM rhodocytin for 3
min. CLEC-2 and Syk were immunoprecipitated (IP), and immunoprecipitates were immunoblotted with an anti-phosphotyrosine antibody. CLEC-2 immu-
noprecipitates were also immunoblotted with anti-CLEC-2 antibody as described under “Experimental Procedures.” The percentage of tyrosine phosphory-
lation was measured at 3 min of stimulation and represented as the means and standard error of three to six independent experiments. **, p  0.005 (sig-
nificant difference versus wild type, according to two-tailed Student’s t test). WB, Western blotting.
SrcFamilyKinasesandSykinCLEC-2Signaling
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 shown in Fig. 4A, the loss of two of the major platelet Src
family kinases did not alter expression of the remaining
major Src family kinases. Interestingly, a further delay in
the onset of aggregation in platelets from a mouse doubly
deficient in Fyn/Lyn or Lyn/Src stimulated with CLEC-2
mAb was observed (Fig. 4, B and D) when compared with
Lyn-deficient platelets (Fig. 3, A and C). In contrast, plate-
lets doubly deficient in Fyn/Src exhibited only a very minor
delay in onset of platelet aggregation (Fig. 4, B and D).
CLEC-2 phosphorylation was abolished in platelets defi-
cient in Fyn/Lyn and Lyn/Src at 180 s (not shown), as was
the case for Lyn-deficient platelets (Fig. 3D), but was un-
changed in platelets deficient in Fyn/Src (Fig. 4E and not
shown). These data demonstrate that Fyn and Src contrib-
ute to platelet activation by the CLEC-2 mAb in the ab-
sence of Lyn but that neither plays a significant role in the
presence of Lyn. In contrast, the response to rhodocytin
was not altered in mouse platelets doubly deficient in Fyn/
Lyn, Lyn/Src, or Fyn/Src. Given that platelet activation by
both CLEC-2 mAb and by rhodocytin is abolished in the
presence of the broad spectrum inhibitor PP2, these results
demonstrate that there are other Src family kinases that
contribute to platelet activation downstream of CLEC-2
and that there may be considerable redundancy between
Src family kinases in mediating this effect.
CD148 Is Dispensable for Platelet Activation by CLEC-2
Ligation—Src family kinases are regulated by phosphorylation
on excitatory and inhibitory tyrosines. Recently, we have
demonstrated a reciprocal increase in phosphorylation of the
inhibitory site and a decrease in phosphorylation of the acti-
vatory site of all Src family kinases in platelets deficient in the
receptor-like protein tyrosine phosphatase CD148. This has a
net effect of greatly reducing the activity of Src family kinases,
leading to a marked inhibition of platelet activation by the
ITAM receptor GPVI and by integrin IIb3 (35). In contrast,
activation of mouse platelets by CLEC-2 mAb (3 and 10 g/
ml) or by rhodocytin (10 and 30 nM) is not significantly al-
tered in the absence of CD148 (Fig. 5 and not shown), demon-
FIGURE 4. A, whole cell lysates prepared from deficient platelets and their litter-matched wild-type platelets were immunoblotted with anti-Lyn, anti-Fyn,
anti-Src, and anti-tubulin antibodies. B and C, washed platelets deficient in Fyn/Lyn, Fyn/Src, and Lyn/Src (2  10
8 platelets/ml) were stimulated with 10
g/ml CLEC-2 mAb (B)o r3 0n M rhodocytin (C). Platelet aggregation was measured as a change in light transmission, using a lumi-aggregometer. Repre-
sentative aggregation traces from three independent experiments are shown. The addition of the agonist is indicated by an arrowhead. D, data represent
the means of the time to get 50% of aggregation and standard error of three independent experiments. **, p  0.005 (significant difference versus wild
type, according to two-tailed Student’s t test). E, Fyn/Src-deficient washed platelets and their litter-matched wild-type platelets (2  10
8 platelets/ml) were
stimulated with 10 g/ml CLEC-2 mAb for 3 min. CLEC-2 was immunoprecipitated (IP), and immunoprecipitates were immunoblotted with an anti-phos-
photyrosine antibody. CLEC-2 immunoprecipitates were also immunoblotted with anti-CLEC-2 antibody as described under “Experimental Procedures.”
Representative data from two independent experiments are shown. WB, Western blotting.
SrcFamilyKinasesandSykinCLEC-2Signaling
4112 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 286•NUMBER 6•FEBRUARY 11, 2011
 
a
t
 
T
h
e
 
U
n
i
v
e
r
s
i
t
y
 
o
f
 
B
i
r
m
i
n
g
h
a
m
,
 
o
n
 
F
e
b
r
u
a
r
y
 
1
0
,
 
2
0
1
1
w
w
w
.
j
b
c
.
o
r
g
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 strating that Src family kinase activity is not rate-limiting for
platelet activation by either of the CLEC-2 receptor ligands.
This therefore provides further evidence for a fundamental
difference in the proximal events underlying platelet activa-
tion by CLEC-2 from those of the platelet ITAM receptor
GPVI.
The Tyrosine Kinase Syk Underlies Phosphorylation of
CLEC-2—The role of the tyrosine kinase Syk in mediating
CLEC-2 phosphorylation and platelet aggregation was investi-
gated using Syk-deficient chimeric mice (Fig. 6A). Phosphor-
ylation of CLEC-2 and aggregation of platelets induced by the
CLEC-2 mAb or by rhodocytin were completely blocked in
Syk-deficient platelets (Fig. 6, B and C), demonstrating that
Syk is essential for phosphorylation of the CLEC-2 hemI-
TAM. Thus, the role of Lyn in mediating phosphorylation of
CLEC-2 in response to the CLEC-2 mAb may be mediated via
phosphorylation of Syk (Fig. 3D), which is regulated by both
autophosphorylation and phosphorylation by Src family ki-
nases (36).
Role of Src Family Kinases in CLEC-2 Signaling Induced by
Podoplanin-expressing Cell Lines and Other Multivalent
Ligands—The differential role of Src family kinases in mediat-
ing phosphorylation of CLEC-2 by CLEC-2 mAb and by
rhodocytin could reflect the degree of cross-linking of
CLEC-2 (37, 38). Thus, the tetrameric rhodocytin (37) is able
to cluster CLEC-2 to a much greater degree than the dimeric
IgG mAb. This is illustrated in platelets treated with the
chemical cross-linker SulfoEGS (Fig. 7A). Rhodocytin induced
a much greater reduction in the monomeric form of CLEC-2
relative to the CLEC-2 mAb, whereas neither ligand induced
clustering of the membrane tyrosine phosphatase CD148 (not
shown), thereby demonstrating that this effect was not due to
nonspecific cross-linking.
In light of this result, we asked whether cross-linking of the
CLEC-2 mAb using an anti-rat Fc antibody would induce a
more powerful degree of platelet activation and whether this
would reduce the dependence on Lyn. The addition of a
cross-linking anti-rat Fc antibody to a concentration of
CLEC-2 mAb that induced shape change converted the re-
sponse to a rapid aggregation. Interestingly, a delay in aggre-
gation was still observed in the absence of Lyn following
cross-linking by an anti-rat Fc antibody (Fig. 7B) and also in
FIGURE 5. CD148 deficiency does not impair CLEC-2 signaling.
A, CD148-deficient washed platelets and their litter-matched wild-type
platelets (2  10
8 platelets/ml) were stimulated with 10 g/ml CLEC-2
mAb or 30 nM rhodocytin. Platelet aggregation was measured as a
change in light transmission, using a lumi-aggregometer. Representa-
tive aggregation traces of four independent experiments are shown. The
addition of the agonist is indicated by an arrowhead. B, CD148-deficient
washed platelets and their litter-matched wild-type platelets (2  10
8
platelets/ml) were stimulated with 10 g/ml CLEC-2 mAb or 30 nM
rhodocytin for 3 min. CLEC-2 and Syk were immunoprecipitated (IP), and
immunoprecipitates were immunoblotted with an anti-phosphotyrosine
antibody. CLEC-2 immunoprecipitates were also immunoblotted with
anti-CLEC-2 mAb as described under “Experimental Procedures.” The
percentage of tyrosine phosphorylation was measured at 3 min of stim-
ulation and represented as means and standard error of four indepen-
dent experiments. WB, Western blotting.
FIGURE 6. Syk is a key regulator of CLEC-2 signaling. A, whole cell lysates
prepared from wild-type and Syk-deficient platelets were immunoblotted
with anti-Syk and anti-tubulin antibodies. B, Syk-deficient washed platelets
and their litter-matched control platelets (2  10
8 platelets/ml) were stimu-
lated with 10 g/ml CLEC-2 mAb. Platelet aggregation was measured as a
change in light transmission, using a lumi-aggregometer. Representative
aggregation traces of three independent experiments are shown. The addi-
tion of the agonist is indicated by an arrowhead. C, after 3 min of stimula-
tion with 10 g/ml CLEC-2 mAb, CLEC-2 was immunoprecipitated (IP) from
Syk-deficient platelets and their litter-matched control platelets (2  10
8
platelets/ml) lysates and immunoblotted with an anti-phosphotyrosine an-
tibody and anti-CLEC-2 mAb as described under “Experimental Procedures.”
A representative blot of three independent experiments is shown. WB,
Western blotting.
SrcFamilyKinasesandSykinCLEC-2Signaling
FEBRUARY 11, 2011•VOLUME 286•NUMBER 6 JOURNAL OF BIOLOGICAL CHEMISTRY 4113
 
a
t
 
T
h
e
 
U
n
i
v
e
r
s
i
t
y
 
o
f
 
B
i
r
m
i
n
g
h
a
m
,
 
o
n
 
F
e
b
r
u
a
r
y
 
1
0
,
 
2
0
1
1
w
w
w
.
j
b
c
.
o
r
g
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 response to a novel pentavalent IgM anti-CLEC-2 antibody
(Fig. 7C), although in both cases this was less than in response
to the IgG antibody (Fig. 3A). Aggregation to the IgM anti-
body was abolished in the presence of the Src family kinase
inhibitor, PP2 (Fig. 7C).
To investigate the dependence of platelet aggregation to
podoplanin on Lyn, we used two podoplanin-expressing
cell lines, namely mouse podoplanin-transfected CHO cells
and human lymphatic endothelial cells. Neither cell line
induced activation of platelets deficient in CLEC-2, con-
firming that activation was via CLEC-2 (not shown). The
two cell lines induce rapid mouse platelet activation, which
was blocked in the presence of PP2, confirming an essential
role for Src family kinases in mediating activation. How-
ever, the response to either of the cell lines was not altered
in the absence of Lyn (Fig. 7D). These data show that the
dependence on Lyn is agonist-dependent, with the depen-
dence being reduced or abolished for ligands that induce
oligomerization of CLEC-2.
DISCUSSION
The present study provides an unequivocal demonstra-
tion that the tyrosine kinase Syk mediates CLEC-2 phos-
phorylation following stimulation by rhodocytin and that
this is independent of Src family kinase activation. Phos-
phorylation of CLEC-2 in response to the snake toxin is
unaltered in platelets deficient or doubly deficient in the
major platelet Src family kinases, namely Fyn, Lyn, and Src,
or in the global regulator of Src kinases, the membrane ty-
rosine phosphatase CD148. The ability of broad spectrum
Src family kinase inhibitors such as PP2 to block platelet
aggregation by rhodocytin is explained by partial or com-
plete inhibition of phosphorylation of Syk and downstream
proteins such as PLC2, respectively. The fact that platelet
aggregation by rhodocytin is not altered in mice deficient
or doubly deficient in the above Src family kinases demon-
strates that one or more other Src family kinases must play
a role in mediating aggregation or that there is consider-
able redundancy between the Src family kinases in mediat-
ing activation. These results reveal a new pathway of plate-
let activation by the hemITAM receptor CLEC-2, which is
distinct from that mediated by the ITAM receptor, GPVI.
CLEC-2 signals through the sequential action of Syk and
Src family kinases, whereas GPVI induces sequential acti-
vation of Src family and Syk kinases, with Src family ki-
nases playing a further role downstream of Syk.
The present study also shows that the role of individual
members of Src family kinases in CLEC-2 signaling is ligand-
FIGURE 7. Role of Src family kinases in CLEC-2-mediated aggregation following multivalent ligands and podoplanin ligation. A, washed platelets
(2  10
8/ml) under basal, CLEC-2 mAb (10 g/ml) or rhodocytin-stimulated (30 nM) conditions had their surface proteins cross-linked with the addition of
1.5 mM Sulfo-EGS cross-linking reagent, with a linker length of 1.6 nm (16 Å) as described under “Experimental Procedures.” Monomeric CLEC-2 was quanti-
fied, and the data represent the means and standard error of three independent experiments. **, p  0.005 (significant difference versus wild type, accord-
ing to two-tailed Student’s t test). mAb, CLEC-2 mAb; Rh, rhodocytin. B, Lyn-deficient washed platelets and their litter-matched wild-type platelets (2  10
8
platelets/ml) were stimulated with 2 g/ml CLEC-2 mAb for 2 min and then with 10 g/ml anti-rat Fc antibody for 5 min. Representative aggregation traces
of three independent experiments are shown. The addition of the agonists is indicated by an arrowhead. C, Lyn-deficient washed platelets and their litter-
matched wild-type platelets (2  10
8 platelets/ml) incubated with or without 20 M PP2 were stimulated with IgM CLEC-2 antibody. The data represent the
means of the time to get 50% of aggregation and standard error of three to six independent experiments. *, p  0.05 (significant difference versus wild
type, according to two-tailed Student’s t test). D, Lyn-deficient platelets and their litter-matched control platelets (2  10
8 platelets/ml) incubated with or
without 20 M PP2 were stimulated in plasma with 1.5  10
5 lymphatic endothelial cells (hLEC) or mouse podoplanin expressing CHO cells (mPodoCHO).
Platelet aggregation was measured as a change in light transmission, using a lumi-aggregometer. Representative aggregation traces of three independent
experiments are shown. The addition of the agonist is indicated by an arrowhead.
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 dependent. Thus, phosphorylation of CLEC-2 in response to
the IgG CLEC-2 antibody is markedly delayed in the absence
of Lyn and further delayed in the combined absence of Fyn/
Lyn or Lyn/Src. On the other hand, phosphorylation is not
altered in mice doubly deficient in Fyn/Src, demonstrating
that neither of these Src family kinases plays a critical role in
the presence of Lyn. The delay in activation seen in the ab-
sence of Lyn is likely to be mediated by a loss of phosphoryla-
tion of Syk, which is regulated by Src family kinases and regu-
lates hemITAM phosphorylation. In contrast, activation of
platelets by rhodocytin is not altered in mice that are either
single or doubly deficient in Fyn, Lyn, or Src, whereas the re-
sponse is abolished in the absence of Syk. Platelet activation
by two podoplanin-expressing cell lines resembles the mecha-
nism underlying activation by rhodocytin in that activation is
also independent of Lyn but blocked by the Src kinase inhibi-
tor, PP2.
The differential role of Lyn and other Src family kinases in
mediating platelet activation by rhodocytin, podoplanin-ex-
pressed cell lines, and the CLEC-2 mAb may be related to the
degree of clustering of CLEC-2. The antibody to CLEC-2 is an
IgG and thus induces dimerization of the receptor, generating
a weak intracellular signal. The further clustering of CLEC-2
with a secondary antibody induces rapid and powerful activa-
tion. In contrast, the tetrameric rhodocytin and polymeric
podoplanin-expressing cells induce a much greater degree of
receptor clustering. The differential dependence on Lyn may
also be due to spatial aspects of the ligand-CLEC-2 interac-
tion, because this may influence the degree of Syk
recruitment.
We have recently reported that phosphorylation of CLEC-2
in human platelets in response to rhodocytin is abolished in
the presence of inhibitors of Src or Syk kinases (20). It was
unclear, however, from this study which of these kinases me-
diated receptor phosphorylation. The demonstration that
phosphorylation of CLEC-2 in mouse platelets by rhodocytin
is abolished in the absence of Syk but not in the presence of
the Src kinase inhibitor PP2 shows that the hemITAM phos-
phorylation is mediated by Syk. The explanation for the dif-
fering dependence of CLEC-2 phosphorylation on Src family
kinases in the two species could reflect, for example, a differ-
ence in the expression levels of CLEC-2 or of Src family and
Syk kinases.
An important question that emerges from this work is how
receptor clustering of CLEC-2 brings about activation of Syk.
One explanation is that it is brought about as a result of mass
action as modeled by Cooper and Qian (39). The key feature
of this model is that a constitutively active kinase is associated
with the receptor in the absence of agonist stimulation. Con-
sistent with this, we have previously reported constitutive
activation of Syk in nonstimulated platelets and transfected
cell lines (40). Thus, although there may be other components
that regulate Src family and Syk kinases upon ligand engage-
ment, this model predicts that clustering alone is sufficient to
mediate receptor phosphorylation. The reason why phos-
phorylation of CLEC-2 is mediated by Syk rather than by one
or more other Src family kinases, as is the case for GPVI-
FcR-chain ITAM, may be related to their juxtaposition in
the cell. For example, we have recently shown that Syk is lo-
calized to plasma membrane in platelets by binding to filamin
A and that a loss of filamin A markedly impairs signaling by
the tyrosine kinase (41).
In summary, this study demonstrates for the first time that
Syk mediates phosphorylation of the CLEC-2 hemITAM and
that Src family kinases play a critical role further downstream
through regulation of Syk and other effector proteins includ-
ing PLC2. It is now of considerable interest to establish
whether this pathway is unique to CLEC-2 or whether it is
also used by other hemITAM receptors.
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